New immunisation reference page: Foetal embryonic cells- utilised in vaccine development platforms
Foetal embryonic cell lines isolated in the early 1960's have been used to develop a number of various vaccines. As scientists work to produce an effective vaccine against SARS CoV-2 it is important to explore as many technologies as possible. Addressing ethical and religious concerns is an essential part of COVID-19 vaccine readiness planning. Our new reference page details the background behind the use of foetal embryonic cells and the role they play in the development of vaccines, the reasons why they are used, as well as addressing any religious and ethical implications.
To access our reference page follow the link to MVEC: Foetal embryonic cells- utilised in vaccine development platforms.
New immunisation reference page: Immunosuppression and vaccines
Having certain medical conditions or taking specific medications can lead to immunosuppression and the decreased ability to fight infections. For these patients, prevention of disease is critical. Our new reference page outlines additional vaccines to consider, and specific vaccines that may be contraindicated.
To learn more follow the link to MVEC：免疫抑制和疫苗
New immunisation reference page: Breastfeeding and immunisations
Immunising breastfeeding mothers can not only protect the mother from vaccine preventable diseases but also provide passive immunity to the baby. Our new reference page details different vaccines and scenarios for consideration when immunising a mother who is breastfeeding.
To learn more follow the link to MVEC: Breastfeeding and immunisation
New immunisation reference page: Eczema and immunisations
Eczema or atopic dermatitis is a common skin condition affecting people of any ages. Whilst it is recognised that vaccines can cause a flare of eczema symptoms, there is no causal relationship identified between eczema and immunisations in the literature.
For further information on eczema and immunisation please refer to our MVEC page 这里
新的免疫参考页面：疫苗开发和安全
为了增强人们对免疫接种安全性和有效性的信心，MVEC 研究了候选疫苗在注册用于疫苗接种计划之前所采取的步骤。许可后监督计划对于及早发现可能出现的任何意外安全信号也很重要。
要了解更多信息，请访问我们的 MVEC 页面 疫苗开发和安全
New immunisation reference page: Live-attenuated vaccines in patients receiving regular red blood cell transfusions
Patients receiving regular red blood cell transfusions to treat chronic medical conditions such as transfusion dependent thalassaemia, sickle cell disease, inherited chronic haemolytic anaemias, or inherited bone marrow failure syndromes are often left unprotected from vaccine preventable diseases due to not meeting the required intervals between red blood cell transfusions. Evidence in this space is limited, however specialist advice suggests that immunisation of this patient group with live-attenuated vaccines is safe and recommended. As such, MVEC has created a new reference page outlining the process of immunisation for these patients. Please refer to MVEC：接受定期红细胞输注的患者的减毒活疫苗 了解更多信息。
Zostavax safety advisory
The Therapeutic Goods Administration (TGA) have reiterated their advice that Zostavax should not be administered to immunocompromised individuals as it is associated with a risk of mild-serious complications. This advice follows a report of a new case of a patient who was taking hydroxychloroquine and a low dose of prednisolone who died three weeks after receiving the Zostavax vaccine. Whilst it was found that the Zostavax was administered in line with existing recommendations it is important that health professionals are aware of the potential of this kind of very rare adverse event.
在这里阅读更多内容：
And for more information on Zoster and to access the Zostavax GP Decision Aid refer to the MVEC：带状疱疹 immunisation reference page.
反映 NIP 变化的 MVEC 免疫参考页面更新 2020 年 7 月 1 日
我们更新了以下 MVEC 免疫参考页面，以反映自 2020 年 7 月 1 日起对国家免疫计划 (NIP) 的更改：
- MVEC：原住民和托雷斯海峡岛民免疫建议
- MVEC：阿斯普利亚
- MVEC：患有心脏病的儿童
- MVEC：脑膜炎球菌病和疫苗
- MVEC：特殊风险和免疫抑制患者的脑膜炎球菌疫苗
- MVEC：早产儿免疫接种
- MVEC：推荐购买 20 岁以下的额外疫苗（无资金）
流感疫苗和鸡蛋过敏
Based on prospective and retrospective studies of influenza vaccination in those with and without egg allergy (including egg anaphylaxis), the presence of egg allergy does not increase the risk of allergic reactions to the influenza vaccine and can be administered in a community immunisation setting, as a single dose, followed by the recommended 15 minute observation period.
For further information please see the following:
新的免疫参考页面：皮内疫苗接种
皮内疫苗接种是将疫苗输送到皮肤外层，用于少数疫苗，例如卡介苗和乙型肝炎（针对无反应者）。
要了解有关皮内疫苗接种、哪些疫苗可以通过这种方式接种以及如何接种皮内疫苗的更多信息，请参阅我们新的免疫接种参考页面， MVEC：皮内免疫接种.